Patents by Inventor William C. Dougall

William C. Dougall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Screening assays for agonists or antagonists or receptor activator of NF-?B
    Patent number: 7572594
    Abstract: The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspects of the invention rely on promoter/reporter constructs using RANK responsive promoters derived from the MMP-9 and TRAP genes. Additional aspects of the invention exploit the ability of RANK to activate c-src activity, F-actin ring formation and CaPO4 resorption.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: August 11, 2009
    Assignee: Immunex Corporation
    Inventor: William C. Dougall
  • Rank-ligand-induced sodium/proton antiporter polypeptides
    Publication number: 20080200389
    Abstract: This invention relates to RIPPA, a new member of the human Na+/H+ antiporter polypeptide family, methods of making such polypeptides, and to methods of using RIPPA and RIPPA-Like polypeptides and agonists or antagonists.
    Type: Application
    Filed: April 7, 2008
    Publication date: August 21, 2008
    Applicant: Immunex Corporation
    Inventors: Timothy A. Bird, Mark E. Tometsko, William C. Dougall, Bruce A. Mosley
  • Screening assays for agonists and antagonists of receptor activator of NF-?B
    Patent number: 6884598
    Abstract: The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspects of the invention rely on promoter/reporter constructs using RANK responsive promoters derived from the MMP-9 and TRAP genes. Additional aspects of the invention exploit the ability of RANK to activate c-src activity, F-actin ring formation and CaPO4 resorption.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: April 26, 2005
    Assignee: Immunex Corporation
    Inventor: William C. Dougall
  • Rank-ligand-induced sodium/proton antiporter polypeptides
    Publication number: 20040157771
    Abstract: This invention relates to RIPPA, a new member of the human Na+/H+ antiporter polypeptide family, methods of making such polypeptides, and to methods of using RIPPA and RIPPA-Like polypeptides and agonists or antagonists.
    Type: Application
    Filed: February 21, 2003
    Publication date: August 12, 2004
    Inventors: Timothy A. Bird, Mark E. Tometsko, William C. Dougall, Bruce A. Mosley
  • METHODS FOR IDENTIFYING COMPOUNDS THAT ANTAGONIZE CD40 SIGNALING
    Publication number: 20030165985
    Abstract: The present invention provides methods for identifying a molecule that antagonizes or agonizes CD40 activity by screening for molecules that modulate the binding of NEMO and CYLD. Also provided are assays useful in screening for the binding of NEMO and CYLD and databases and methods useful for analyzing the resultant information.
    Type: Application
    Filed: May 8, 2001
    Publication date: September 4, 2003
    Inventors: Jonathan M.J. Derry, William C. Fanslow, William C. Dougall
  • Receptor activator of NF-&kgr;B
    Patent number: 6537763
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: March 25, 2003
    Assignee: Immunex Corporation
    Inventors: William C. Dougall, Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky
  • Receptor activator of NF-&kgr;B
    Patent number: 6528482
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: March 4, 2003
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky, William C. Dougall
  • Use of rank antagonists to treat cancer
    Publication number: 20030021785
    Abstract: Provided herein are methods of treating cancer by administering an effective amount of an agent that antagonizes the interaction between RANK and RANKL.
    Type: Application
    Filed: June 5, 2002
    Publication date: January 30, 2003
    Inventor: William C. Dougall
  • Therapeutic use of rank antagonists
    Publication number: 20030017151
    Abstract: Provided herein are methods of treating various medical conditions that require the formation of new bone by administering an effective amount of a RANK antagonist. Antagonists suitable for use in the subject methods include soluble RANK polypeptides that bind RANKL, antisense oligonucleotides that inhibit RANK activity, antibodies specific for RANK or RANKL and osteoprotegerin.
    Type: Application
    Filed: May 17, 2002
    Publication date: January 23, 2003
    Inventors: William C. Dougall, Dirk M. Anderson
  • Receptor activator of NF-&kgr;B
    Patent number: 6479635
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: November 12, 2002
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky, William C. Dougall
  • Screening assays for agonists and antagonists of receptor activator of NF-kappa B
    Publication number: 20020086312
    Abstract: The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspects of the invention rely on promoter/reporter constructs using RANK responsive promoters derived from the MMP-9 and TRAP genes. Additional aspects of the invention exploit the ability of RANK to activate c-src activity, F-actin ring formation and CaPO4 resorption.
    Type: Application
    Filed: September 20, 2001
    Publication date: July 4, 2002
    Inventor: William C. Dougall
  • Receptor activator of NF-kappaB
    Publication number: 20020081720
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Application
    Filed: May 31, 2001
    Publication date: June 27, 2002
    Applicant: Immunex Corporation
    Inventors: William C. Dougall, Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky
  • Receptor activator of NF-&kgr;B
    Patent number: 6271349
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: August 7, 2001
    Assignee: Immunex Corporation
    Inventors: William C. Dougall, Laurent Galibert